Cargando…

MTN-001: Randomized Pharmacokinetic Cross-Over Study Comparing Tenofovir Vaginal Gel and Oral Tablets in Vaginal Tissue and Other Compartments

BACKGROUND: Oral and vaginal preparations of tenofovir as pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) infection have demonstrated variable efficacy in men and women prompting assessment of variation in drug concentration as an explanation. Knowledge of tenofovir concentrat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hendrix, Craig W., Chen, Beatrice A., Guddera, Vijayanand, Hoesley, Craig, Justman, Jessica, Nakabiito, Clemensia, Salata, Robert, Soto-Torres, Lydia, Patterson, Karen, Minnis, Alexandra M., Gandham, Sharavi, Gomez, Kailazarid, Richardson, Barbra A., Bumpus, Namandje N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3559346/ https://www.ncbi.nlm.nih.gov/pubmed/23383037 http://dx.doi.org/10.1371/journal.pone.0055013

Ejemplares similares

Correlation between Compartmental Tenofovir Concentrations and an Ex Vivo Rectal Biopsy Model of Tissue Infectibility in the RMP-02/MTN-006 Phase 1 Study
por: Richardson-Harman, Nicola, et al.
Publicado: (2014)

Discovery of Genetic Variants of the Kinases That Activate Tenofovir in a Compartment-specific Manner
por: Lade, Julie M., et al.
Publicado: (2015)

Divergent adherence estimates with pharmacokinetic and behavioural measures in the MTN-003 (VOICE) study
por: van der Straten, Ariane, et al.
Publicado: (2016)

A Mechanistic In Vivo/Ex Vivo Pharmacokinetic‐Pharmacodynamic Model of Tenofovir for HIV Prevention
por: Jayachandran, Priya, et al.
Publicado: (2021)

A Phase 1 Randomized, Double Blind, Placebo Controlled Rectal Safety and Acceptability Study of Tenofovir 1% Gel (MTN-007)
por: Mcgowan, Ian, et al.
Publicado: (2013)

Vaginal microbiota and mucosal pharmacokinetics of tenofovir in healthy women using tenofovir and tenofovir/levonorgestrel vaginal rings
por: Thurman, Andrea Ries, et al.
Publicado: (2019)

A Multi-Compartment Single and Multiple Dose Pharmacokinetic Comparison of Rectally Applied Tenofovir 1% Gel and Oral Tenofovir Disoproxil Fumarate
por: Yang, Kuo-Hsiung, et al.
Publicado: (2014)

Acceptability of the Dapivirine Vaginal Ring in Postmenopausal US Women
por: Shapley-Quinn, Mary Kate, et al.
Publicado: (2022)

Vaginal Microbiota and Mucosal Pharmacokinetics of Tenofovir in Healthy Women Using a 90-Day Tenofovir/Levonorgestrel Vaginal Ring
por: Thurman, Andrea R., et al.
Publicado: (2022)

HIV Protective Efficacy and Correlates of Tenofovir Blood Concentrations in a Clinical Trial of PrEP for HIV Prevention
por: Donnell, Deborah, et al.
Publicado: (2014)

Vaginal deployment and tenofovir delivery by microbicide gels
por: Gao, Y., et al.
Publicado: (2015)

Evaluation of Rapidly Disintegrating Vaginal Tablets of Tenofovir, Emtricitabine and Their Combination for HIV-1 Prevention
por: Clark, Meredith R., et al.
Publicado: (2014)

Chitosan-Based Mucoadhesive Vaginal Tablets for Controlled Release of the Anti-HIV Drug Tenofovir
por: Cazorla-Luna, Raúl, et al.
Publicado: (2019)

Tenofovir Activation is Diminished in the Brain and Liver of Creatine Kinase Brain-Type Knockout Mice
por: Eberhard, Colten D., et al.
Publicado: (2023)

Release of Tenofovir from Carrageenan-Based Vaginal Suppositories
por: Zaveri, Toral, et al.
Publicado: (2014)

Transgender women on oral HIV pre‐exposure prophylaxis have significantly lower tenofovir and emtricitabine concentrations when also taking oestrogen when compared to cisgender men
por: Shieh, Eugenie, et al.
Publicado: (2019)

Multicompartmental Pharmacokinetic Model of Tenofovir Delivery by a Vaginal Gel
por: Gao, Yajing, et al.
Publicado: (2013)

Spatial Distribution Profiles of Emtricitabine, Tenofovir, Efavirenz, and Rilpivirine in Murine Tissues Following In Vivo Dosing Correlate with Their Safety Profiles in Humans
por: Seneviratne, Herana Kamal, et al.
Publicado: (2020)

Population pharmacokinetics of tenofovir and tenofovir‐diphosphate in healthy women
por: Burns, Rebecca N., et al.
Publicado: (2015)

Discovery of genetic variants of the kinases that activate tenofovir among individuals in the United States, Thailand, and South Africa: HPTN067
por: Figueroa, Dominique B., et al.
Publicado: (2018)

The MTN and MTR bending magnets
por: Keizer, Reinder L, et al.
Publicado: (1978)

Association between vaginal washing and vaginal bacterial concentrations
por: Sabo, Michelle C., et al.
Publicado: (2019)

Tenofovir vaginal film as a potential MPT product against HIV-1 and HSV-2 acquisition: formulation development and preclinical assessment in non-human primates
por: Patel, Sravan Kumar, et al.
Publicado: (2023)

Silicon Oxycarbide Porous Particles and Film Coating as Strategies for Tenofovir Controlled Release in Vaginal Tablets for HIV Prevention
por: Martín-Illana, Araceli, et al.
Publicado: (2022)

Phase 1 pharmacokinetics and safety study of extended duration dapivirine vaginal rings in the United States
por: Liu, Albert Y, et al.
Publicado: (2021)

MTN magnet for the SPS extracted beam.
por: CERN PhotoLab
Publicado: (1976)

Increased Dapivirine Tissue Accumulation through Vaginal Film Codelivery of Dapivirine and Tenofovir
por: Akil, Ayman, et al.
Publicado: (2014)

High levels of adherence to a rectal microbicide gel and to oral Pre-Exposure Prophylaxis (PrEP) achieved in MTN-017 among men who have sex with men (MSM) and transgender women
por: Carballo-Diéguez, Alex, et al.
Publicado: (2017)

Potential role of tenofovir vaginal gel for reduction of risk of herpes simplex virus in females
por: Tan, DHS
Publicado: (2012)

298 Identifying vaginal microbiome profiles that influence tenofovir distribution in the female genital tract
por: Lantz, Alyssa M., et al.
Publicado: (2023)

Prevalence of HIV-1 Drug Resistance among Women Screening for HIV Prevention Trials in KwaZulu-Natal, South Africa (MTN-009)
por: Parikh, Urvi M., et al.
Publicado: (2013)

Multiple use applicator for vaginal tablets/vaginal inserts: compliance verification and suitability studies
por: Brunner, Heiko, et al.
Publicado: (2020)

Phase I trial of pod-intravaginal rings delivering antiretroviral agents for HIV-1 prevention: Rectal drug exposure from vaginal dosing with tenofovir disoproxil fumarate, emtricitabine, and maraviroc
por: Vincent, Kathleen Listiak, et al.
Publicado: (2018)

Vaginal washing and lubrication among female sex workers in the Mexico-US border region: implications for the development of vaginal PrEP for HIV prevention
por: Pines, Heather A., et al.
Publicado: (2018)

Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women
por: Thurman, Andrea Ries, et al.
Publicado: (2018)

Correction: Prevalence of HIV-1 Drug Resistance among Women Screening for HIV Prevention Trials in KwaZulu-Natal, South Africa (MTN-009)
por: Parikh, Urvi M., et al.
Publicado: (2014)

Efficacy of Tenofovir 1% Vaginal Gel in Reducing the Risk of HIV-1 and HSV-2 Infection
por: McConville, Christopher, et al.
Publicado: (2014)

Acceptability of an extended duration vaginal ring for HIV prevention and interest in a multi-purpose ring
por: Stoner, Marie C. D., et al.
Publicado: (2022)

Urethro-Vaginal, Vesico-Vaginal, and Recto-Vaginal Fistulæ, &c.
Publicado: (1861)

Misoprostol vaginal insert versus misoprostol vaginal tablets for the induction of labour: a cohort study
por: Bolla, Daniele, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_7i1pll1rbkegjgqq9ci4cggd5g